Efficacy of daclatasvir in hepatitis C virus

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 9, 2014, Pages 1025-1031

  Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

asunaprevir; chronic hepatitis C; DAA; daclatasvir; genotype 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; MACROGOL DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; VIRUS PROTEIN; VIRUS RNA;

ADVERSE OUTCOME; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HUMAN; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; METABOLISM; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84905825880     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.942282     Document Type: Article

References (31)

1. Ghany MG, Strader DB, Thomas DL, Seef LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
2. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46
3. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12: 671-5
4. Namiki I, Nishiguchi S, Hino K, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:347-68
5. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002;99:11584-9
6. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to IFN-A is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87
7. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustaiend virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84
8. Manns MP, HcHutchson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 2001;358:958-65
9. Fried MW, Schiffmann ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavrin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
10. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
11. Poordad FJr, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
12. Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol 2012;84:1097-105
13. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-20
14. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65
15. Asahina Y, Izumi M, Umeda N, et al. Pharmakokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007;14: 396-403
16. Honda M, Sakai A, Yomashita T, Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499-509
17. Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir conbined with peginterferon alfa-2a and ribavirn in Japanese patients infected with hepatitis C genotype 1. Antivir Ther 2014. [Epub ahead of print]
18. Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginteerferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014. [Epub ahead of print]
19. McPhee F, Hernandez D, Zhou N, et al. HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or 2b. Antiviral Ther 2014. [Epub ahead of print]
20. McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responder receiving daclatasvir and asunaprevir. Hepatology 2013;58:902-11
21. Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370: 211-21
23. Dore GJ, Lawitz E, Hezole C, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013;58:S570-1
24. Cahyama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstuructual protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8
25. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62
26. Karino Y, Toyota J, Ikeda F, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivarals daclatasvir and asunaprevir. J Hepatol 2013;58:646-54
27. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59(6):2083-91
28. Wang C, Huang H, Valera L, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012;56:1350-8
29. Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012;54:352-4
30. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon-and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-nä?ve patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9
31. Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-12